 FLORHAM PARK, N.J., May 13, 2021 GLOBE NEWSWIRE -- PDS Biotechnology Corporation Nasdaq: PDSB, a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, will discuss its financial results for the quarter ended March 31, 2021 and provide a business update on its conference call today. 